FT商學院

BioNTech chief predicts need for updated Covid vaccines next year

Ugur Sahin says the virus is very likely to mutate and evade immunity given by current jabs

The chief executive of the biotech behind the first Covid-19 vaccine has said a new formulation is likely to be needed by the middle of next year to protect against the virus as it mutates.

Ugur Sahin, chief executive of BioNTech, told the Financial Times that as time passes, mutations will emerge that can evade the body’s immune defences. “This year [a different vaccine] is completely unneeded. But by mid next year, it could be a different situation,” he predicted.

A partnership between the German biotech and US pharmaceutical company Pfizer brought the first Covid-19 vaccine to market. It was also the first vaccine based on mRNA technology to win regulatory approval, and has been the world’s best-selling drug this year.

您已閱讀28%(730字),剩餘72%(1904字)包含更多重要資訊,訂閱以繼續探索完整內容,並享受更多專屬服務。
版權聲明:本文版權歸FT中文網所有,未經允許任何單位或個人不得轉載,複製或以任何其他方式使用本文全部或部分,侵權必究。
設置字型大小×
最小
較小
默認
較大
最大
分享×